Pfizer, Astellas say Xtandi regimen hit secondary goal in late-stage trial for prostate cancer

9 hours ago 2
Cancer cells vis

koto_feja

Pfizer (NYSE:PFE) and Astellas Pharma (OTCPK:ALPMF) (OTCPK:ALPMY) announced on Thursday that their jointly developed antitumor agent Xtandi reached its secondary goal as part of a combination therapy in a late-stage trial for certain patients with prostate cancer.

Citing topline data

Recommended For You

More Trending News

Read Entire Article